Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 329,004 | 233,662 | 2,785 | 6,689 | 152 |
| Cost of Goods | 38,486 | 14,131 | 265 | 790 | N/A |
| Gross Profit | 290,518 | 219,531 | 2,520 | 5,899 | 152 |
| Operating Expenses | 249,075 | 199,029 | 221,101 | 351,459 | 273,746 |
| Operating Income | 41,929 | 20,633 | -218,316 | -344,770 | -273,594 |
| Interest Expense | 24,028 | 12,615 | 10,191 | 5,638 | 6,329 |
| Other Income | 7,693 | 5,044 | 4,695 | 2,307 | 542 |
| Pre-tax Income | 25,594 | 13,062 | -223,812 | -348,101 | -279,381 |
| Income Tax | 2,211 | 390 | N/A | N/A | N/A |
| Net Income Continuous | 23,383 | 12,672 | -223,812 | -348,101 | -279,381 |
| Net Income | $23,383 | $12,672 | $-223,812 | $-348,101 | $-279,381 |
| EPS Basic Total Ops | 0.16 | 0.09 | -1.65 | -2.63 | -2.42 |
| EPS Basic Continuous Ops | 0.16 | 0.09 | -1.65 | -2.63 | -2.42 |
| EPS Diluted Total Ops | 0.15 | 0.09 | -1.65 | -2.63 | -2.42 |
| EPS Diluted Continuous Ops | 0.15 | 0.09 | -1.65 | -2.63 | -2.42 |
| EPS Diluted Before Non-Recurring Items | 0.15 | 0.09 | -1.46 | -2.63 | -2.42 |
| EBITDA(a) | $37,220 | $21,198 | $-216,288 | $-342,679 | $-272,325 |